Table 1.
Baseline characteristics of study participants
| Variable | HIV– (n = 23) | HIV+ (n = 68) | p | IRb (n = 42) | INR (n = 20) | LLV (n = 5) | LTNP (n = 1) |
|---|---|---|---|---|---|---|---|
| Age | 0.982 | ||||||
| Median (IQR) | 62.0 (58.0, 70.0) | 63.0 (58.0, 69.0) | 62.0 (57.0, 68.0) | 63.0 (60.5, 67.5) | 66.0 (63.0, 70.0) | 76.0 (76.0, 76.0) | |
| Range | (55.0, 77.0) | (54.0, 85.0) | (54.0, 85.0) | (55.0, 78.0) | (62.0, 73.0) | (76.0, 76.0) | |
| CD4 counta | – | ||||||
| Median (IQR) | 527 (364, 665) | 635 (519, 833) | 316 (252, 410) | 511 (325, 565) | 597 (597, 597) | ||
| Range | (74.0, 1784) | (347, 1784) | (74.0, 502) | (322, 764) | (597, 597) | ||
| CD4 nadir | – | ||||||
| Median (IQR) | 148 (65.0, 240) | 210 (110, 290) | 31.0 (10.0, 130) | 91.0 (70.0, 120) | 470 (470, 470) | ||
| Range | (0.0, 1090) | (0.0, 1090) | (0.0, 200) | (10.0, 220) | (470, 470) | ||
| CD4 percentagea | – | ||||||
| Median (IQR) | 30.0 (22.0, 38.5) | 36.7 (29.8, 42.9) | 19.9 (17.6, 24.8) | 24.7 (17.4, 26.1) | 35.2 (35.2, 35.2) | ||
| Range | (12.9, 62.3) | (21.2, 62.3) | (12.9, 30.1) | (15.3, 48.2) | (35.2, 35.2) | ||
| CD4/CD8 ratioa | – | ||||||
| Median (IQR) | 0.9 (0.5, 1.2) | 1.1 (0.9, 1.5) | 0.5 (0.4, 0.6) | 0.5 (0.3, 0.5) | 1.0 (1.0, 1.0) | ||
| Range | (0.2, 6.1) | (0.4, 6.1) | (0.2, 1.1) | (0.3, 1.9) | (1.0, 1.0) | ||
| HIV subgroup, n (%) | – | ||||||
| Immune responders (IR) | 42 (61.8) | ||||||
| Immune non-responders (INR) | 20 (29.4) | ||||||
| Low-level viremics (LLV) | 5 (7.4) | ||||||
| Long-term non-progressors (LTNP) | 1 (1.5) | ||||||
| Vaccine D1/D2, n (%) | 0.766 | ||||||
| mRNA/mRNA | 13 (56.5) | 35 (51.5) | 21 (50.0) | 11 (55.0) | 2 (40.0) | 1 (100) | |
| ChAdOx1/ChAdOx1 | 9 (39.1) | 27 (39.7) | 17 (40.5) | 7 (35.0) | 3 (60.0) | 0 (0.0) | |
| ChAdOx1/mRNA | 1 (4.3) | 6 (8.8) | 4 (9.5) | 2 (10.0) | 0 (0.0) | 0 (0.0) | |
| Vaccine D3, n (%) | 1.000 | ||||||
| None | 0 (0.0) | 1 (1.5) | 1 (2.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| BNT162b2 | 19 (82.6) | 54 (79.4) | 29 (69.0) | 20 (100) | 5 (100) | 0 (0.0) | |
| mRNA-1273 | 4 (17.4) | 13 (19.1) | 12 (28.6) | 0 (0.0) | 0 (0.0) | 1 (100) | |
| Time lapse between D1 and D2 (days) | 0.819 | ||||||
| Median (IQR) | 63.0 (53.0, 65.0) | 60.0 (54.0, 71.0) | 61.0 (53.0, 74.0) | 58.0 (52.5, 67.5) | 65.0 (56.0, 75.0) | 59.0 (59.0, 59.0) | |
| Range | (30.0, 78.0) | (28.0, 98.0) | (28.0, 92.0) | (28.0, 98.0) | (56.0, 84.0) | (59.0, 59.0) | |
| Time lapse between D3 and V9 (days) | 0.076 | ||||||
| Median (IQR) | 118 (107, 130) | 130 (112, 150) | 121 (110, 135) | 152 (138, 165) | 125 (112, 133) | 117 (117, 117) | |
| Range | (97.0, 189) | (82.0, 180) | (82.0, 179) | (96.0, 179) | (110, 180) | (117, 117) | |
| N+ and/or post-COVID-19, n (%) | 6 (26.1) | 10 (14.7) | 7 (16.7) | 1 (5.0) | 2 (40.0) | 0 (0.0) | |
| First visit number with N+/post-COVID-19, n (%) | |||||||
| None | 17 (73.9) | 58 (85.3) | 35 (83.3) | 19 (95.0) | 3 (60.0) | 1 (100) | |
| V1 | 1 (4.3) | 1 (1.5) | 1 (2.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| V4 | 0 (0.0) | 1 (1.5) | 0 (0.0) | 1 (5.0) | 0 (0.0) | 0 (0.0) | |
| V8 | 0 (0.0) | 1 (1.5) | 1 (2.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| V8a | 1 (4.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| V8b | 0 (0.0) | 2 (2.9) | 1 (2.4) | 0 (0.0) | 1 (20.0) | 0 (0.0) | |
| V9 | 4 (17.4) | 5 (7.4) | 4 (9.5) | 0 (0.0) | 1 (20.0) | 0 (0.0) |
p values are based on Fisher’s exact test for categorical variables and on Wilcoxon sum rank test for continuous variables. Related to Figures 1A and 1B, Table S1, and STAR Methods.
a
If baseline data were not available, the data at screening were used instead (n = 24).
b
IR = PWH who are immunological responders, INR = immunological non-responders, LLV = PWH with low-level viremia, LTNP = long-term non-progressors.